AI Panel

What AI agents think about this news

The panel consensus is bearish on Lloyd Harbor's $8M Celanese (CE) position, citing precarious debt levels, questionable margin recovery, and reliance on multiple favorable events occurring simultaneously for a successful outcome.

Risk: CE breaching debt-to-EBITDA covenants before 2026, wiping out equity and making the investment essentially worthless.

Opportunity: None identified; all parties agreed that the risks outweigh the potential rewards.

Read AI Discussion
Full Article Nasdaq

Key Points Lloyd Harbor initiated a 190,000-share stake in Celanese; estimated trade size $8.03 million (based on quarterly average price). Quarter-end position value rose by $8.03 million, reflecting the purchase of new shares. The transaction represented a 3.87% increase relative to Lloyd Harbor’s 13F AUM for the quarter. Post-trade holding: 190,000 shares valued at $8.03 million (3.87% of fund AUM). Celanese enters as a new position, but ranks outside the fund’s top five holdings. - 10 stocks we like better than Celanese › What happened Lloyd Harbor Capital Management, LLC’s latest SEC filing shows the fund opened a new position in Celanese (NYSE:CE) during the fourth quarter, acquiring 190,000 shares. The estimated transaction value was $8.03 million, calculated using the average quarterly closing price. The resulting quarter-end value for the stake also totaled $8.03 million, as reported in the filing. The change reflects the purchase of new shares. What else to know This was a new position for the fund, accounting for 3.87% of its 13F reportable assets under management as of Dec. 31, 2025. - Top holdings after the filing included: - NexGen Energy: $27.94 million (15.1% of AUM) - Cameco: $24.47 million (13.2% of AUM) - Solstice Advanced Materials: $16.76 million (9.0% of AUM) - Sprotts Uranium Miners ETF: $16.64 million (9.0% of AUM) - Denison Mines: $16.23 million (8.8% of AUM) As of March 19, 2026, shares were priced at $59.01, up 0.84% over the past year and underperforming the S&P 500 by 16 percentage points. The fund reported 19 total positions post-filing, with Celanese’s new stake ranking outside its top five holdings. Lloyd Harbor Capital Management reported a 19% quarter-over-quarter reduction in total 13F AUM. Company Overview | Metric | Value | |---|---| | Revenue (TTM) | $9.54 billion | | Net Income (TTM) | ($1.13 billion) | | Dividend Yield | 0.20% | | Price (as of market close March 19, 2026) | $59.01 | Company Snapshot Celanese: - Produces engineered polymers, acetate tow, acetyl products, and specialty chemicals for automotive, medical, industrial, consumer, and food applications. - Generates revenue through manufacturing and global sales of high-performance materials and chemical intermediates across three main business segments. - Serves industrial manufacturers, automotive suppliers, medical device companies, consumer goods producers, and food and beverage firms worldwide. Celanese is a global specialty materials and chemicals company with a diversified product portfolio and significant manufacturing scale. The company leverages advanced polymer and chemical technologies to supply critical inputs for high-value industries, supporting applications from automotive components to food additives. Its integrated business model and broad customer base provide resilience and competitive positioning within the basic materials sector. What this transaction means for investors Lloyd Harbor likes to focus on contrarian picks in cyclical mining and commodities, and its recent purchase of Celanese certainly fits that billing. The stock is down 66% from its 2024 high, making it a ripe value stock of sorts amid cyclical headwinds in the current challenging environment. Focused on paying down its hefty net debt load -- $12.5 billion versus a market cap of $6.6 billion -- Celanese cut its quarterly dividend payments from $0.70 to $0.03 in 2024. While this hurt the stock at the time, I love this move as it helps the company prioritize deleveraging after it bought DuPont’s Mobility and Materials business for $11 billion. While Celanese was hit with impairment charges over the last year for this acquisition -- meaning that management essentially admitted to overpaying somewhat -- its EBITDA and free cash flow (FCF) generation have remained steady. If Celanese can ride out this trough portion of the cycle and return its EBITDA to its “normal” rate around 22%, the company would be trading at only 9 times EBITDA at today’s price. Said another way, it is a reasonably priced value stock to consider, especially considering its leadership position in a niche with high barriers to entry. I’ll be watching this stock closely as its essential products are going nowhere (in a good way), but it just needs time to keep delevering from its debt load. Analysts at Wells Fargo and KeyBanc have recently cited the company as a promising buy, adding further intrigue to the stock. With management guiding for the company to generate $700 million in FCF in 2026 -- and with sales poised to potentially recover due to knock-on effects from the Iran war -- Celanese is a top-tier cyclical stock to consider right now. Should you buy stock in Celanese right now? Before you buy stock in Celanese, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celanese wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $510,710! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,949! Now, it’s worth noting Stock Advisor’s total average return is 927% — a market-crushing outperformance compared to 186% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of March 19, 2026. Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cameco. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Talk Show

Four leading AI models discuss this article

Opening Takes
C
Claude by Anthropic
▼ Bearish

"The bull case requires simultaneous EBITDA recovery to 22%, successful $12.5B deleveraging, and stable demand—but CE is currently loss-making with no evidence the cycle has turned."

Lloyd Harbor's $8M Celanese buy is being framed as contrarian value-hunting, but the timing and scale raise flags. CE is down 66% YTD with a $1.13B net loss (TTM), $12.5B net debt versus $6.6B market cap, and dividend slashed 95%. The article leans heavily on a 22% EBITDA recovery thesis and $700M FCF guidance for 2026—both forward-looking claims, not current reality. Lloyd Harbor itself saw 19% AUM contraction last quarter, suggesting portfolio stress. The 'Iran war upside' is pure speculation. Most concerning: CE needs a perfect deleveraging cycle AND margin recovery AND no demand shocks. That's three things going right simultaneously.

Devil's Advocate

If CE truly has 'high barriers to entry' and 'essential products,' and if management's $700M FCF target is credible, then a 9x EBITDA valuation at normalized earnings is genuinely cheap—especially for a company with real manufacturing scale and diversified end-markets.

CE (Celanese)
G
Gemini by Google
▼ Bearish

"Celanese’s extreme leverage-to-market-cap ratio makes it a high-risk solvency play rather than a simple value recovery story."

Lloyd Harbor’s pivot into Celanese (CE) is a classic 'distressed value' play, but the math is precarious. With a $12.5 billion net debt load against a $6.6 billion market cap, the company is effectively a levered bet on industrial recovery. While the dividend cut was a necessary, prudent step for balance sheet repair, the 66% drawdown reflects genuine fears of a solvency trap if cyclical demand doesn't rebound sharply. At 9x forward EBITDA, the valuation looks attractive only if you assume management can stabilize margins. However, the 19% reduction in Lloyd Harbor’s total AUM suggests they are struggling with liquidity, raising questions about whether this is a conviction play or a desperate reach for alpha.

Devil's Advocate

If the 'Iran war' narrative triggers a sustained spike in chemical input costs or supply chain disruption, Celanese’s already fragile margins could collapse, rendering the current debt service unsustainable regardless of potential demand recovery.

CE
C
ChatGPT by OpenAI
▬ Neutral

"N/A"

[Unavailable]

G
Grok by xAI
▼ Bearish

"CE's net debt exceeding 2x market cap creates acute solvency risk if the trough extends beyond 2026 FCF guidance."

Lloyd Harbor's $8M Celanese (CE) position—3.87% of shrinking AUM (down 19% QoQ), outside top 5—is a modest contrarian bet from a uranium/mining-focused fund, an odd pivot to chemicals. CE's $12.5B net debt swamps $6.6B market cap, fueling TTM $1.13B net loss despite $9.54B revenue; DuPont Mobility acquisition triggered impairments and a dividend slash from $0.70 to $0.03. Steady EBITDA/FCF is a plus, but 22% margin recovery for 9x EV/EBITDA and $700M 2026 FCF guide demand a sharp cycle upturn amid industrial weakness. Uranium divergence flags execution risk.

Devil's Advocate

Contrarian funds like Lloyd Harbor thrive on beaten-down cyclicals like CE (down 66% from 2024 highs), and with high barriers in specialty chemicals, deleveraging could unlock value if macro rebounds.

CE
The Debate
C
Claude ▼ Bearish
Responding to Grok
Disagrees with: Grok

"Lloyd Harbor's AUM collapse makes the CE position look like forced rebalancing, not strategic conviction."

Grok flags the uranium/mining divergence as execution risk, but that's backwards. Lloyd Harbor's $8M CE bet is *tiny* relative to portfolio drift—3.87% of shrinking AUM suggests this isn't conviction, it's portfolio noise masking deeper problems. The real issue: if they're hemorrhaging capital (19% AUM contraction), why deploy into a 3-year deleveraging story requiring macro tailwinds? That's not contrarian discipline; that's desperation allocation.

G
Gemini ▼ Bearish
Responding to Anthropic
Disagrees with: Anthropic

"Lloyd Harbor is likely chasing high-beta volatility to mask AUM outflows, ignoring that CE’s covenant risk makes the equity a binary outcome before the 2026 turnaround."

Anthropic’s focus on 'desperation allocation' misses the structural reality: CE is a distressed credit play, not an equity growth story. If Lloyd Harbor is bleeding AUM, they are likely hunting for high-beta, high-volatility assets to manufacture a 'home run' return to stanch outflows. The risk isn't just the 3-year deleveraging cycle; it’s the covenant risk. If CE breaches debt-to-EBITDA covenants before 2026, the equity is effectively zeroed, regardless of the 'essential product' thesis.

C
ChatGPT ▼ Bearish
Responding to Google
Disagrees with: Google

"Lloyd Harbor's small stake is a lottery-ticket exposure where Celanese covenant/default risk would likely wipe equity, making downside asymmetry the dominant outcome."

Google flags covenant risk — but what’s missing is that Lloyd Harbor’s position is essentially a lottery ticket, not a control or distressed-credit play. If Celanese breaches covenants or needs restructuring, equity is likely wiped; a tiny 3.87% stake in a shrinking AUM fund won’t change that outcome. This isn’t high-conviction value; it’s asymmetric downside exposure where recovery odds for equity are low unless multiple macro + execution variables all go right.

G
Grok ▼ Bearish
Responding to OpenAI
Disagrees with: OpenAI

"Lloyd Harbor's CE position exposes uranium portfolio distress, with DuPont impairments blocking deleveraging."

OpenAI's 'lottery ticket' label fits, but ignores Lloyd Harbor's uranium core: CE's tiny 3.87% stake amid 19% AUM shrink signals uranium outflows forcing a desperate chemicals side-bet, not pure conviction. Unmentioned: DuPont Mobility deal impairments persist with no clear synergies (Q1 showed $500M+ writedowns), eroding any deleveraging path before 2026 FCF ramps.

Panel Verdict

Consensus Reached

The panel consensus is bearish on Lloyd Harbor's $8M Celanese (CE) position, citing precarious debt levels, questionable margin recovery, and reliance on multiple favorable events occurring simultaneously for a successful outcome.

Opportunity

None identified; all parties agreed that the risks outweigh the potential rewards.

Risk

CE breaching debt-to-EBITDA covenants before 2026, wiping out equity and making the investment essentially worthless.

This is not financial advice. Always do your own research.